Ann Lloyd CBE, Cadeirydd | Chair

**** 01633 435 957

☑ Ann.Lloyd@wales.nhs.uk

Nicola Prygodzicz, Prif Weithredwr | Chief Executive

℃ 01633 435 958 **У** CEOabuhb

Our ref: FOI 24-201

☑ Nicola.Prygodzicz@wales.nhs.uk



Friday 23rd February 2024

Your request

You requested the following:

- A. How many patients have been treated with the following drugs in the past 4 months:
 - Atogepant (Aquipta) any disease
 - Erenumab (Aimovig) any disease
 - Eptinezumab (Vyepti) any disease
 - Fremanezumab (Ajovy) any disease
 - Galcanezumab (Emgality) any disease
 - Rimegepant (Vydura) any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) migraine ONLY
- B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		



Bwrdd Iechyd Prifysgol Aneurin Bevan yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Aneurin Bevan

Aneurin Bevan University Health Board

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Clarification

We advised you that we are unable to provide information on drugs administered, but are able to provide information on drugs supplied. On 16 February 2024, you clarified that you are happy to receive information on supplied drugs.

Our response

We have conducted a search of our records and have established that we do hold some information relating to your request, as set out below.

A. Our partial response to this question is provided in the attached spreadsheet.

In relation to the element which requests the number of patients prescribed with Botulinum Toxin for migraines, we are unable to provide information on drugs dispensed for a specific condition as we do not hold this information centrally and we would need to search individual patient records to obtain this information. We have established that it would take in excess of 18 hours to access this information and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.

- B. We are unable to provide information on drugs dispensed for a specific condition as we do not hold this information centrally and we would need to search individual patient records to obtain this information. We have established that it would take in excess of 18 hours to access this information and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.
- C. Yes